357 related articles for article (PubMed ID: 17503047)
1. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.
Royer B; Delroeux D; Guardiola E; Combe M; Hoizey G; Montange D; Kantelip JP; Chauffert B; Heyd B; Pivot X
Cancer Chemother Pharmacol; 2008 Mar; 61(3):415-21. PubMed ID: 17503047
[TBL] [Abstract][Full Text] [Related]
2. [Intraperitoneal chemotherapy of CDDP and etoposide in patients with advanced ovarian cancer].
Hirashima Y; Shimura T; Tanaka Y; Demukai H; Kubota T; Kobayashi T; Suzuki A
Gan To Kagaku Ryoho; 1993 Aug; 20(10):1321-6. PubMed ID: 8346930
[TBL] [Abstract][Full Text] [Related]
3. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
Deng C; Huang R; Lian L
Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):159-62. PubMed ID: 8758790
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study.
de Bree E; Rosing H; Filis D; Romanos J; Melisssourgaki M; Daskalakis M; Pilatou M; Sanidas E; Taflampas P; Kalbakis K; Beijnen JH; Tsiftsis DD
Ann Surg Oncol; 2008 Apr; 15(4):1183-92. PubMed ID: 18239973
[TBL] [Abstract][Full Text] [Related]
6. Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer.
Andreopoulou E; Chen T; Liebes L; Curtin J; Blank S; Wallach R; Hochster H; Muggia F
Cancer Chemother Pharmacol; 2011 Aug; 68(2):457-63. PubMed ID: 21069334
[TBL] [Abstract][Full Text] [Related]
7. Intraoperative chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I study.
Guardiola E; Chauffert B; Delroeux D; Royer B; Heyd B; Combe M; Benoit L; Causeret S; Demarchi M; Magnin G; Mayer F; Tixier H; Pivot X
Anticancer Drugs; 2010 Mar; 21(3):320-5. PubMed ID: 20032778
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration: development of a limited sampling strategy for toxicity risk assessment.
Royer B; Jullien V; Guardiola E; Heyd B; Chauffert B; Kantelip JP; Pivot X
Clin Pharmacokinet; 2009; 48(3):169-80. PubMed ID: 19385710
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
[TBL] [Abstract][Full Text] [Related]
11. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
12. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
13. Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer.
Zeimet AG; Reimer D; Radl AC; Reinthaller A; Schauer C; Petru E; Concin N; Braun S; Marth C
Anticancer Res; 2009 Jul; 29(7):2803-8. PubMed ID: 19596965
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological bases of intraperitoneal chemotherapy].
Gladieff L; Chatelut E; Dalenc F; Ferron G
Bull Cancer; 2009 Dec; 96(12):1235-42. PubMed ID: 19923051
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacokinetic analysis of intra-peritoneal administration of cisplatin].
Terashima M; Ikeda K; Takagane A; Sasaki N; Abe K; Araya M; Nishizuka S; Yonezawa H; Irinoda T; Nakaya T; Oyama K; Saito K
Gan To Kagaku Ryoho; 1997 Sep; 24(12):1859-62. PubMed ID: 9382551
[TBL] [Abstract][Full Text] [Related]
16. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal chemotherapy for advanced epithelial ovarian malignancy: lessons learned.
Bunting M; Chan W; Brand A; Blomfield P
Aust N Z J Obstet Gynaecol; 2009 Dec; 49(6):667-71. PubMed ID: 20070720
[TBL] [Abstract][Full Text] [Related]
18. Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer.
Sugiyama T; Kumagai S; Nishida T; Ushijima K; Matsuo T; Yakushiji M; Hyon SH; Ikada Y
Anticancer Res; 1998; 18(4B):2837-42. PubMed ID: 9713471
[TBL] [Abstract][Full Text] [Related]
19. [The pharmacokinetics of intraperitoneal (IP) carboplatin (CBDCA) and dose-up study of intravenous (IV) cyclophosphamide (CPM) in combination with IP CBCDA for advanced ovarian cancer patients].
Fujiwara K; Yamauchi H; Sawada S; Koike H; Mohri H; Ohishi Y; Kohno I
Gan To Kagaku Ryoho; 1992 Dec; 19(14):2373-9. PubMed ID: 1463344
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study.
Miyagi Y; Fujiwara K; Kigawa J; Itamochi H; Nagao S; Aotani E; Terakawa N; Kohno I;
Gynecol Oncol; 2005 Dec; 99(3):591-6. PubMed ID: 16095677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
